Next-generation sequencing (eg clonoSEQ) to detect measurable residual disease (MRD) at a threshold of 10-4 as an alternative test in individuals with acute lymphoblastic leukemia may be considered medically necessary.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of less than 10-4 in individuals with acute lymphoblastic leukemia is considered investigational.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of 10-4 as an alternative test in individuals with chronic lymphocytic leukemia may be considered medically necessary.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of less than 10-4 in individuals with chronic lymphocytic leukemia is considered investigational.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of 10-5 as an alternative test in individuals with multiple myeloma may be considered medically necessary.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of less than 10-5 in individuals with multiple myeloma is considered investigational.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of 10-4 in individuals with diffuse large B-cell lymphoma is considered investigational.
Next-generation sequencing (eg clonoSEQ) to detect MRD at a threshold of 10-4 in individuals with mantle cell lymphoma is considered investigational.
Next-generation sequencing to detect MRD is considered investigational in all other situations.
